Details

Autor(en) / Beteiligte

• Yamamoto, Nobuyuki
• Harada, Hideyuki
• Okamoto, Isamu
• Masuda, Noriyuki
• Hayakawa, Kazushige
• Satouchi, Miyako
• Soejima, Toshinori
• Nishio, Makoto
• Kozuka, Takuyo
• Takeda, Koji
• Tanaka, Masahiro
• Seto, Takashi
• Sasaki, Tomonari
• Tsubouchi, Hiroshi
• Kakurai, Yasuyuki
• Nishimura, Yasumasa
• Nakagawa, Kazuhiko

Titel

Phase 2 Study of Nimotuzumab in Combination With Concurrent Chemoradiotherapy in Patients With Locally Advanced Non–Small-Cell Lung Cancer

Ist Teil von

• Clinical lung cancer, 2021-03, Vol.22 (2), p.134-141

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2021

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• We evaluated the tolerability and efficacy of nimotuzumab, a humanized IgG1 monoclonal anti–epidermal growth factor receptor antibody, with concurrent chemoradiotherapy in patients with unresectable locally advanced non–small-cell lung cancer. In this multicenter, single-arm, open-label, phase 2 trial conducted in Japan (JapicCTI-090825), patients received thoracic radiotherapy (60 Gy, 2 Gy per fraction, 6 weeks) and four 4-week cycles of chemotherapy (day 1, cisplatin 80 mg/m2; days 1 and 8, vinorelbine 20 mg/m2). Nimotuzumab 200 mg was administrated weekly for 16 weeks. The primary endpoint was treatment completion rate, defined as the percentage of patients completing 60 Gy of radiotherapy within 8 weeks, 2 cycles of chemotherapy, and at least 75% of the required nimotuzumab dose during the initial 2-cycle concurrent chemoradiotherapy period. Of 40 patients enrolled, 39 received the study treatment, which was well tolerated, with a completion rate of 87.2%. Thirty-eight patients completed 60 Gy of radiotherapy within 8 weeks. Infusion reaction, grade 3 or higher rash, grade 3 or higher radiation pneumonitis, or grade 4 or higher nonhematologic toxicity were not observed. The objective response rate was 69.2%. The median progression-free survival (PFS) and 5-year PFS rate were 508 days and 29.0%, respectively. The 5-year PFS rate in patients with non–squamous cell carcinoma (n = 23) was 13.7% and in patients with squamous cell carcinoma (n = 16) was 50.0%. The 5-year overall survival rate was 58.4%. Addition of nimotuzumab to the concurrent chemoradiotherapy regimen was well tolerated and showed potential for treating patients with locally advanced non–small-cell lung cancer, particularly squamous cell carcinoma. [Display omitted] Nimotuzumab is a recombinant human monoclonal antibody against epidermal growth factor receptor. We conducted a phase 2 trial of nimotuzumab in combination with chemoradiotherapy in 39 patients with locally advanced non–small-cell lung cancer. Treatment was well tolerated. The 5-year progression-free survival (PFS) rate and 5-year overall survival (OS) rate were 29.0% and 58.4%, respectively. Favorable OS and PFS outcomes were particularly noted in patients with squamous cell carcinoma.